Characterization of the ferrokinetic profile of patients with chronic kidney disease
DOI:
https://doi.org/10.61182/rnavmed.v10n1a2Keywords:
Chronic Kidney Disease, Iron deficiency, Ferrokinetic profile, Ferritin, TransferrinAbstract
Background: Chronic Kidney Disease (CKD) is a progressive pathology that significantly affects quality of life and is associated with complications such as iron deficiency and anemia. This study analyzes the ferrokinetic profile in patients with CKD, evaluating factors such as ferritin levels and transferrin saturation.
Objective: to describe the demographic and clinical particularities of patients diagnosed with Chronic Kidney Disease (CKD) stages 2 to 5, as well as their ferrokinetic profile.
Methods: a cross-sectional observational study was conducted in a hospital in Bogota. The sample included 139 patients over 18 years of age with a diagnosis of CKD and evaluation of the ferrokinetic profile. Demographic, clinical and laboratory results were collected.
Results: the mean age was 68.2 years, predominantly male (66.9%). There was a high prevalence of iron deficiency (57.2%), associated with elevated ferritin levels (372.9 ± 363.3 mg/dL) and low transferrin saturation (19.2 ± 13%). The most frequent comorbidities were type 2 diabetes mellitus (33%) and coronary heart disease (42.4%). Mortality was 14.4%.
Conclusions: iron deficiency is frequent in patients with CKD and is associated with inflammation and erythropoietin deficiency, which increases the burden of morbidity and mortality. Adequate management of iron deficiency and comorbidities is essential to improve the prognosis in this population, highlighting the importance of a comprehensive approach in its treatment.
References
(1) Alvis-Peña D, Calderón-Franco C. Descripción de factores de riesgo para mortalidad en adultos con enfermedad renal crónica en estadio 3 - 5. Acta Medica Peru. 2020;37. https://doi.org/10.35663/amp.2020.372.980
(2) Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089–100. https://doi.org/10.1111/j.1523-1755.2005.00365.x
(3) MINSALUD. Minsalud propende por la protección de la salud renal. Boletín Prensa No 168 2022. Bogotá: MINSALUD. 2022. Disponible en: https://www.minsalud.gov.co/Paginas/Minsalud-propende-por-la-proteccion-de-la-salud-renal.aspx#:~:text=En%20Colombia%2C
(4) Ammirati AL. Chronic Kidney Disease. Rev Assoc Med Bras. 2020;66Suppl 1:s03–9. https://doi.org/10.1590/1806-9282.66.S1.3
(5) Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143:1157–72. https://doi.org/10.1161/CIRCULATIONAHA.120.050686
(6) Garrido DI, Fontalvo N, Espinoza I, Arias L, Valarezo S, Osorio W, et al. Descripción de la ferropenia en pacientes con enfermedad renal crónica terminal en hemodiálisis, Quito, Ecuador. Rev Colomb Nefrol. 2019;6:95–102. https://doi.org/10.22265/acnef.6.2.342
(7) Cases A, Egocheaga MI, Tranche S, Pallarés V, Ojeda R, Górriz JL, et al. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología. Nefrol. 2018;38:8–12. https://doi.org/10.1016/j.nefro.2017.09.004
(8) Cases-Amenós A, Martínez-Castelao A, Fort-Ros J, Bonal-Bastons J, Ruiz MP, Vallés-Prats M, et al. Prevalencia de anemia y su manejo clínico en la enfermedad renal crónica estadios 3-5 no en diálisis en Cataluña: estudio MICENAS I . Nefrol. 2014;34:189–98.
(9) Cases A, Egocheaga MI, Tranche S, Pallarés V, Ojeda R, Górriz JL, et al. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología. Nefrol. 2018;38:8–12. https://doi.org/10.1016/j.nefro.2017.09.004
(10) Cobo Marcos M, de la Espriella R, Gayán Ordás J, Llàcer P, Pomares A, Fort A, et al. Prevalencia y perfil clínico de la enfermedad renal en pacientes con insuficiencia cardiaca crónica. Datos del Registro cardiorrenal español. Rev Española Cardiol. 2024;77:50–9. https://doi.org/10.1016/j.recesp.2023.05.004
(11) Matsushita K, Ballew SH, Wang AY-M, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol 2022;18:696–707. https://doi.org/10.1038/s41581-022-00616-6
(12) Venkatesan M, Saxena S, Kumar A. Evaluation of iron status in patients of chronic kidney disease - A study to assess the best indicators including serum transferrin receptor assay. Indian J Nephrol. 2019;29(4): 248-253. https://doi.org/10.4103/ijn.IJN_159_18
(13) Calderón Franco CH, Baquero-Lopera GA, Machuca-Marulanda SM, Martínez-López HC. Asociación entre los pacientes ferropénicos con diagnóstico de insuficiencia cardiaca aguda y las escalas New York Heart Association (NYHA) y la fracción de eyección del ventrículo izquierdo (FEVI). Acta Médica Colomb. 2023;49. https://doi.org/10.36104/amc.2024.3091
(14) Guaricci AI, Sturdà F, Russo R, Basile P, Baggiano A, Mushtaq S, et al. Assessment and management of heart failure in patients with chronic kidney disease. Heart Fail Rev. 2023;29:379–94. https://doi.org/10.1007/s10741-023-10346-x
(15) Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119:2017–32. https://doi.org/10.1093/cvr/cvad083
(16) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81. https://doi.org/10.1016/S0140-6736(10)60674-5
(17) Kishi S, Kadoya H, Kashihara N. Treatment of chronic kidney disease in older populations. Nat Rev Nephrol. 2024;20:586–602. https://doi.org/10.1038/s41581-024-00854-w
(18) Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020;31:456–68. https://doi.org/10.1681/ASN.2019020213
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Carlos Hernán Calderón-Franco, María José Castro-Salas, Juan David López-Restrepo, Johanis Yuleidi Polo-Bossio, Lorena Marcela Ramírez-González, Gary A. Baquero-Lopera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
